Lexicon Pharmaceuticals
LXRX
137 hedge funds and large institutions have $453M invested in Lexicon Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 20 reducing their positions, and 14 closing their positions.
745% more call options, than puts
Call options by funds: $2.34M | Put options by funds: $277K
135% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 20
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
8% more funds holding
Funds holding: 127 → 137 (+10)
2.67% more ownership
Funds ownership: 77.17% → 79.84% (+2.7%)
4% less capital invested
Capital invested by funds: $471M → $453M (-$17.9M)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.9M |
| 2 |
O
OrbiMed
New York
|
+$9.22M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.33M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.16M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.58M |
Top Sellers
| 1 |
AG
Artal Group
Luxembourg
|
-$69.3M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$13.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.15M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.12M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.15M |
LXRX Hedge Fund Activity: Q3 2024 in Review
137 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2024, worth a combined $453M — down 3.8% from $471M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LXRX positions and 14 closed out — a net gain of 11 holders — while 47 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $19.9M. The largest seller was Artal Group, cutting an estimated $69.3M.
- 137 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2024, up from 127 in Q2 2024.
- Funds reported $453M of Lexicon Pharmaceuticals stock for Q3 2024, down 3.8% quarter-over-quarter.
- 25 funds opened new Lexicon Pharmaceuticals positions in Q3 2024 and 14 closed out, a net change of +11 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2024 was Fidelity Investments, an estimated $19.9M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2024 was Artal Group, an estimated $69.3M sold.
Based on aggregated 13F filings for Q3 2024.